PATENTS ENCOURAGE INVESTMENT IN NEW DRUG DEVELOPMENT , WHILE THEIR EXPIRATION MAKES LIFE-SAVING MEDICINES MORE AFFORDABLE .
D I S S E C T I N G B U S I N E S S with real-time monitoring and extended autonomy , for example , may not be necessary but the focus may be instead on improving logistics efficiencies .
Another key consideration is partnering with trusted distribution partners with efficient logistics operations and a large enough fleet size to ensure timely delivery and reduced transportation costs . For example , regions with many generic manufacturers may experience increased competition , requiring even more efficient and cost-effective distribution solutions . Collaborating with logistics partners that can adapt to these regional challenges and offer flexible , scalable services becomes vital in sustaining profitability .
Preparing for unexpected events , such as the disruptions in the Red Sea , is essential . In a post-patent environment , the focus should shift to building resilience in the supply chain to handle increased competition and potential shocks . This means finding alternative transportation routes and using advanced risk management tools to keep the supply chain robust and adaptable to real-time changes in demand and transport conditions .
Additionally , managing inventory levels at distribution centres becomes critical to prevent stockouts or accumulating excess stock . By carefully analysing sales data and market trends , companies can adjust their distribution network to better match demand fluctuations after patent expiration . This helps keep products available when needed without overstocking , which would tie up valuable resources .
Looking ahead , technologies like IoT , Blockchain for traceability and AI for predictive analytics will significantly enhance logistics operations , making pharma distribution more robust and reliable . Using data analytics to simplify processes , cut costs and boost performance will be especially important in the post-patent cliff landscape . These advancements will help companies better navigate the complexities of increased competition and market pressures , helping them stay competitive and efficient .
PATENTS ENCOURAGE INVESTMENT IN NEW DRUG DEVELOPMENT , WHILE THEIR EXPIRATION MAKES LIFE-SAVING MEDICINES MORE AFFORDABLE .
requires cold storage , and this proportion is expected to rise . Nearly half of all new medicines in the next three years will require cold storage and distribution .
Manufacturers need to bear this in mind and use the coming decade to prepare for the patent cliff . By establishing robust , adaptable cold chain processes now , companies can help future-proof the drugs ’ cost-efficiency and product integrity when these reach the end of their patent life .
Beyond the patent cliff
As medicines approach the end of their patent life , pharmaceutical manufacturers must make critical decisions on how to manage these patent cliffs . The goal is to continue providing quality medications while sustaining their business to be able to support the next generation of life saving medicines
In this context , improving logistics is one reliable and effective method for navigating this challenging period . The end of a patent may appear daunting , but it doesn ’ t have to mark the end of a product ’ s lifecycle . With smart logistics and innovative strategies , it can be an opportunity for a fresh start . �
As the pharmaceutical landscape evolves , efficient logistics , particularly cold chain logistics , will become increasingly important . Currently , about one in three medicines
www . intelligenthealth . tech 31